Evidence map›Paper›PMID 41533248›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026

Efficacy and risks of drug holiday in the management of medication-related osteonecrosis of the jaw in cancer patients: a single-center retrospective study.

Hironobu Hata, Kenji Imamachi, Kazuhito Yoshikawa, Mayumi Kamaguchi, Toshihisa Osanai, Masashi Matsuzaka, Kenichi Watanabe, Nobumoto Tomioka, Toru Harabayashi, Katsuya Fujimoto and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Hironobu HataDepartment of Dentistry and Oral Surgery, NHO Hokkaido Cancer Center, 3-54 Kikusui4-Jyo 2-Tyoume, Shiroishi-Ku, Sapporo, Hokkaido, 003-0804, Japan. hata.hironobu.wq@mail.hosp.go.jp.ORCID http://orcid.org/0000-0002-0077-7026
Kenji ImamachiDepartment of Dentistry and Oral Surgery, NHO Hokkaido Cancer Center, 3-54 Kikusui4-Jyo 2-Tyoume, Shiroishi-Ku, Sapporo, Hokkaido, 003-0804, Japan.ORCID http://orcid.org/0000-0003-1090-3660
Kazuhito YoshikawaDepartment of Dentistry and Oral Surgery, NHO Hokkaido Cancer Center, 3-54 Kikusui4-Jyo 2-Tyoume, Shiroishi-Ku, Sapporo, Hokkaido, 003-0804, Japan.
Mayumi KamaguchiDepartment of Dentistry and Oral Surgery, NHO Hokkaido Cancer Center, 3-54 Kikusui4-Jyo 2-Tyoume, Shiroishi-Ku, Sapporo, Hokkaido, 003-0804, Japan.ORCID http://orcid.org/0000-0003-4055-9047
Toshihisa OsanaiDivision of Orthopaedic Surgery, K&A Clinic, Medical Corporation Mirai, 2-6-1 Nisshin-Cho, Tomakomai, Hokkaido, 053-0833, Japan.ORCID http://orcid.org/0000-0003-0220-0535
Masashi MatsuzakaClinical Research Support Centre, Hirosaki University Hospital, 53 Honcho, Hirosaki, Aomori, 036-8563, Japan.ORCID http://orcid.org/0000-0002-8199-3037
Kenichi WatanabeDepartment of Breast Surgery, NHO Hokkaido Cancer Center, 3-54 Kikusui4-Jyo 2-Tyoume, Shiroishi-Ku, Sapporo, Hokkaido, 003-0804, Japan.
Nobumoto TomiokaDepartment of Breast Surgery, NHO Hokkaido Cancer Center, 3-54 Kikusui4-Jyo 2-Tyoume, Shiroishi-Ku, Sapporo, Hokkaido, 003-0804, Japan.
Toru HarabayashiDepartment of Urology, NHO Hokkaido Cancer Center, 3-54 Kikusui4-Jyo 2-Tyoume, Shiroishi-Ku, Sapporo, Hokkaido, 003-0804, Japan.ORCID http://orcid.org/0000-0002-5839-2954
Katsuya FujimotoDepartment of Hematology, NHO Hokkaido Cancer Center, 3-54 Kikusui4-Jyo 2-Tyoume, Shiroishi-Ku, Sapporo, Hokkaido, 003-0804, Japan.
Satoshi OizumiDepartment of Respiratory Medicine, NHO Hokkaido Cancer Center, 3-54 Kikusui4-Jyo 2-Tyoume, Shiroishi-Ku, Sapporo, Hokkaido, 003-0804, Japan.
Michihiro UedaDepartment of Clinical Oral Oncology, NHO Hokkaido Cancer Center, 3-54 Kikusui 4-Jo 2-Chome, Shiroishi-Ku, Sapporo, Hokkaido, 003-0804, Japan.ORCID http://orcid.org/0009-0006-6080-3413
Hiroaki HiragaDepartment of Orthopaedic Surgery, NHO Hokkaido Cancer Center, 3-54 Kikusui4-Jyo 2-Tyoume, Shiroishi-Ku, Sapporo, Hokkaido, 003-0804, Japan.ORCID http://orcid.org/0000-0003-1825-1070
Ikuya MiyamotoDepartment of Oral Pathobiological Science, Faculty of Dental Medicine, Oral Diagnosis and Medicine, Hokkaido University, Nishi 7-Tyoume Kita13-Jyo, Kita-Ku, Sapporo, Hokkaido, 060-8586, Japan.ORCID http://orcid.org/0000-0003-4642-8611

Funding

Japan Society for the Promotion of Science (JSPS) KAKENHI JP22K10137
6 · The paper itself

Abstract

purposeDiscontinuing bone-modifying agents (BMAs) during management of medication-related osteonecrosis of the jaw (MRONJ) remains controversial. This retrospective study evaluates the impact and potential risks of BMA drug holidays in cancer patients with MRONJ.

methodsWe retrospectively classified 156 cancer patients with MRONJ into four groups: BMA withdrawal with conservative therapy (WC, n = 40), withdrawal with surgical therapy (WS, n = 63), non-withdrawal with conservative therapy (nWC, n = 30), and non-withdrawal with surgical therapy (nWS, n = 23). In the WS group, surgery was performed after radiographic confirmation of bone sequestration following BMA discontinuation. Healing rates and skeletal-related events (SREs) incidence were analyzed.

resultsThe healing rates from MRONJ onset were 94.7% in the WS group, 53.6% in the nWS group, 25.5% in the WC group, and 0% in the nWC group. Among surgical patients, the healing rate from the time of surgery was significantly higher in the WS group (92.3%) than in the nWS group (47.8%) (hazard ratio = 3.23, p < 0.05). The incidence of SREs was 52.3% in the WC group, 15.8% in the WS group, 16.7% in the nWS group, and 4.2% in the nWC group. The WC group showed a significantly higher incidence of SREs compared with the WS and nWS groups.

conclusionA therapeutic strategy involving planned BMA discontinuation followed by delayed surgical intervention after radiographic confirmation of sequestrum formation, may be associated with improved healing outcomes. This approach does not appear to increase the incidence of SREs, particularly when BMA therapy is appropriately resumed after successful surgical healing.

Indexed as

Bisphosphonate-Associated Osteonecrosis of the JawBone Density Conservation AgentsNeoplasmsAgedAged, 80 and overFemaleHumansIncidenceMaleMiddle AgedRetrospective StudiesTreatment InterruptionBone Density Conservation AgentsBisphosphonatesCancerDenosumabDrug holidayMedication-related osteonecrosis of the jawSkeletal-related events

Identifiers

PMID41533248

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.